**Kansas Bill Seeks to Classify Kratom as Schedule 1 Drug, Raising Alarm for Industry**

Kansas Bill Seeks to Classify Kratom as Schedule 1 Drug, Raising Alarm for Industry

TOPEKA, KS – The kratom industry and consumers are closely watching developments in Kansas, where Senate Bill 497 (SB 497) proposes classifying kratom as a Schedule 1 controlled substance, placing it in the same category as heroin, methamphetamine, and cocaine. The bill, which was heard by the Senate Public Health and Welfare Committee on Monday, February 16, 2026, also specifically targets 7-hydroxymitragynine (7-OH), an alkaloid found in kratom.

What Happened: SB 497 aims to amend the Kansas Uniform Controlled Substances Act to include both kratom and 7-OH as Schedule 1 substances. Proponents of the bill, including the youth services division chief for the Kansas Attorney General's Office, argue that widespread retail access to kratom will lead to opioid-like consequences, including addiction, overdoses, and preventable deaths. A representative from the Clinical Reference Laboratory in Lenexa also testified to seeing more 7-OH recently than oxycodone, hydrocodone, and fentanyl combined. Opponents, however, contend that the bill incorrectly equates kratom with its more potent synthesized derivative, 7-OH, and that a complete ban would eliminate access to a substance many use for pain relief and as an alternative to opioids.

Why It Matters to Kratom Merchants and Consumers: If SB 497 passes, it would have profound implications. Kratom sales, possession, and manufacturing would become illegal throughout Kansas, leading to potential criminal charges for individuals and businesses involved. This would effectively dismantle the legal kratom market within the state, cutting off access for consumers who rely on it. For the broader kratom community, this legislative effort in Kansas underscores the ongoing regulatory challenges and the persistent threat of prohibition, potentially setting a precedent that could influence other states.

Compliance Implications: For Kansas-based merchants, the passage of SB 497 would necessitate an immediate cessation of all kratom-related operations, as any continued activity would be illegal. For merchants operating in states where kratom remains legal, this development serves as a stark reminder of the industry's "high-risk" classification and the dynamic nature of its legal status. It highlights the critical importance of vigilant monitoring of legislative actions at both state and local levels, as regulations can shift rapidly and dramatically.

What High-Risk Merchants Need to Know About COAs, Lab Testing, and Regulatory Compliance: In the face of such legislative challenges, robust compliance practices are not just good business; they are essential for industry survival and advocacy. High-risk kratom merchants must prioritize comprehensive third-party lab testing and transparent Certificates of Analysis (COAs). These COAs should meticulously verify the absence of harmful contaminants such as heavy metals, pesticides, and microbial pathogens, and accurately detail the alkaloid content, specifically addressing concerns around 7-OH levels.

Adherence to Good Manufacturing Practices (GMP) and any existing state-level Kratom Consumer Protection Acts (KCPAs) is non-negotiable. Proactive engagement in self-regulation and demonstrating a commitment to product quality and consumer safety can serve as powerful counterarguments against calls for outright bans. By consistently providing safe, accurately labeled products, the industry can differentiate itself from unregulated markets and advocate for sensible regulation over prohibition, emphasizing responsible practices as a cornerstone for long-term viability.